Capsida inks deal with Lilly's Prevail

5 January 2023

US biotech star-up Capsida Biotherapeutics has entered a multi-year strategic collaboration with pharma major Eli Lilly’s (NYSE: LLY) subsidiary Prevail to develop transformative genetic medicines for serious diseases.

The aim is for Prevail to leverage Capsida's novel adeno-associated virus (AAV) engineering platform to identify and advance clinically translatable capsids paired with Prevail's cargo to develop best-in-class, IV-administered gene therapies directed to specified targets known to cause serious diseases that affect the central nervous system (CNS).

Capsida emerged from stealth mode in May 2021 with $140 million of capital, including $90 million from AbbVie (NYSE: ABBV). By June last year, it had already struck a deal with Swiss-American biotech CRISPR Therapeutics (Nasdaq: CRSP) on in vivo gene editing therapies delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK